TABLE 3.

The effect of covariates on the responsiveness of RNFL and GCIPL to DMTs.

Outcomes	RNFL				GCIPL
Moderator	Estimate	95% CI	p	k	Estimate	95% CI	p	k
Age	0.03	−0.10 to 0.16	0.60	19	−0.005	−0.05 to 0.04	0.79	17
Female	0.49	−4.29 to 5.27	0.83	19	1.06	−1.09 to 3.21	0.31	19
ON history	0.08	−4.52 to 4.69	0.97	17	0.87	−0.63 to 2.37	0.23	19
Time to active phase	0.09	−0.45 to 0.63	0.73	19	0.02	−0.02 to 0.06	0.30	19
Follow‐up time	0.10	−0.40 to 0.60	0.68	19	0.06	−0.10 to 0.23	0.45	19
Disease duration	0.01	−0.27 to 0.28	0.95	19	−0.02	−0.06 to 0.02	0.33	17
Baseline EDSS score	0.13	−0.82 to 1.08	0.77	19	0.0013	−0.45 to 0.45	0.99	12
Baseline RNFL thickness	0.001	−0.13 to 0.13	0.99	19	—	—	—	—
Baseline GCIPL thickness	—	—	—	—	−0.02	−0.18 to 0.15	0.85	18
OCT device‐Heidelberg	−0.07	−1.08 to 0.94	0.88	19	−0.10	−0.31 to 0.11	0.32	19
OCT device‐stratus	−0.69	−8.29 to 6.91	0.85	19	—	—	—	—
Study quality	−0.0005	−0.17 to 0.17	0.99	19	0.003	−0.03 to 0.05	0.86	19

Note: k = number of populations in which the respective moderator variable was reported.

Abbreviations: CI, confidence interval; DMT, disease‐modifying therapies; EDSS, Expanded Disability Status Scale; GCIPL, ganglion cell‐inner plexiform layer; OCT, optic coherence tomography; ON, optic neuritis; RNFL, retinal nerve fiber layer.